- In March 2025, ResMed, a leading health technology company, announced a comprehensive brand evolution aimed at unifying its brand portfolio to serve more people and healthcare providers worldwide. This initiative underscores ResMed's commitment to delivering innovations in respiratory therapy, including high-flow nasal cannula solutions, and expanding awareness of sleep and breathing health as mainstream priorities
- In February 2025, a study published in Hospital Pediatrics highlighted efforts to improve the use of HFNC in children with bronchiolitis, pneumonia, and asthma, aiming to decrease HFNC length of treatment and length of stay. This initiative reflects the ongoing clinical efforts to optimize HFNC therapy and ensure its value in diverse pediatric respiratory conditions
- In February 2025, a study in ERS Publications investigated the physiological effects of high-flow nasal cannula during sustained high-intensity exercise in healthy volunteers. The research concluded that HFNC intervention reduces respiratory effort and dyspnoea and improves temporal ventilation distribution, showcasing potential broader applications of HFNC beyond acute respiratory failure
- In April 2025, Vapotherm, Inc. introduced the Unicorn Cannula, an innovative single-prong cannula designed to enhance CO2 clearance and patient comfort. This product highlights Vapotherm's commitment to developing cutting-edge patient interfaces that optimize HFNC delivery and improve clinical outcomes
- In October 2023, the FDA granted 510(k) clearance to the Bonhawa high-flow oxygen therapy system. Designed to enhance the treatment of patients with respiratory insufficiency, this approval signifies continued innovation and expansion of available HFNC devices in key markets
